Nedosiran (DCR-PHXC) is a GalNAc-dsRNA conjugate designed for RNA interference-based silencing of lactate dehydrogenase (LDH), enabling selective hepatic targeting and reduction of oxalate production, Nedosiran is extensively studied as a potential therapeutic approach for patients with primary hyperoxaluria and end-stage renal disease to address metabolic dysregulation at the RNA level.
CAS Number:
[2266591-83-5]
Target:
Dehydrogenase
T39802
* VAT and and shipping costs not included. Errors and price changes excepted
